Inventor · disambiguated record
Lars Christian Petersen
Also filed as: PETERSEN LARS C · PETERSEN LARS CHRISTIAN
25 granted patents·17 pending applications·966 citations·filing 1989–2018
97Inventor score
Files withNOVO NORDISK AS21NOVO NORDISK HEALTHCARE AG5ZYMOGENETICS INC5HILDEN IDA2NOVO NORDISK HEALTH CARE A G1
Top patents by PatentIndex Score
42 records- 0196US5817788AModified factor VIIZYMOGENETICS INC·Filed 1994·Granted Oct 6, 1998·121 cites·9 claims
- 0295US5833982AModified factor VIIZYMOGENETICS INC·Filed 1996·Granted Nov 10, 1998·133 cites·15 claims
- 0392US5788965AModified factor VIINOVO NORDISK AS·Filed 1995·Granted Aug 4, 1998·112 cites·15 claims
- 0491US5576294AHuman Kunitz-type protease inhibitor variantNOVO NORDISK AS·Filed 1994·Granted Nov 19, 1996·97 cites·12 claims
- 0590US5861374AModified Factor VIINOVO NORDISK AS·Filed 1994·Granted Jan 19, 1999·136 cites·5 claims
- 0688US5997864AModified factor VIINOVO NORDISK AS·Filed 1997·Granted Dec 7, 1999·71 cites·9 claims
- 0784US9896513B2Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitorNOVO NORDISK AS·Filed 2014·Granted Feb 20, 2018·7 cites·20 claims
- 0883US5373090AAprotinin analogues and a process for the production thereofNOVO NORDISK AS·Filed 1989·Granted Dec 13, 1994·47 cites·6 claims
- 0980US6858587B2Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosisNOVO NORDISK PHARMACEUTICALS I·Filed 2002·Granted Feb 22, 2005·23 cites·10 claims
- 1080US5618696AHuman kunitz-type protease inhibitor and variants thereofNOVO NORDISK AS·Filed 1995·Granted Apr 8, 1997·35 cites·17 claims
- 1179US6183743B1Modified factor VIIZYMOGENETICS INC·Filed 1999·Granted Feb 6, 2001·42 cites·8 claims
- 1279US5629176AHuman Kunitz-type protease inhibitor variantsNOVO NORDISK AS·Filed 1994·Granted May 13, 1997·39 cites·9 claims
- 1378US9228022B2Antibodies that are capable of specifically binding tissue factor pathway inhibitorNOVO NORDISK AS·Filed 2013·Granted Jan 5, 2016·3 cites·3 claims
- 1462US6461610B1Methods for modifying cell motility using factor VIIa or inactivated factor VIIaNOVO NORDISK AS·Filed 1999·Granted Oct 8, 2002·27 cites·2 claims
- 1561US6268163B1Identification of drug candidates modulating factor VII-mediated intracellular signalingNOVO NORDISK AS·Filed 1998·Granted Jul 31, 2001·19 cites·4 claims
- 1660US2004197370A1Modified factor VIINOVO NORDISK HEALTHCARE AG·Filed 2003·Application pending·0 cites
- 1759US10106606B2Targeting tissue factor to activated plateletsNOVO NORDISK AS·Filed 2016·Granted Oct 23, 2018·0 cites·12 claims
- 1859US7829529B2Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxisNOVO NORDISK HEALTH CARE A G·Filed 2008·Granted Nov 9, 2010·0 cites·3 claims
- 1959US2003092627A1Pharmaceutical composition comprising a factor VIIa and a factor XIIIFiled 2002·Application pending·0 cites
- 2059US2019062429A1Targeting tissue factor to activated plateletsNOVO NORDISK AS·Filed 2018·Application pending·0 cites
- 2157US2007280920A1PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIIINOVO NORDISK HEALTHCARE AG·Filed 2007·Application pending·0 cites
- 2256US2004087498A1Modified factor VIINOVO NORDISK HEALTHCARE AG·Filed 2002·Application pending·0 cites
- 2354US10717784B2Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitorNOVO NORDISK AS·Filed 2018·Granted Jul 21, 2020·0 cites·10 claims
- 2454US5859010AFactor VII -binding reagentNOVO NORDISK AS·Filed 1997·Granted Jan 12, 1999·17 cites·20 claims
- 2554US5591603AProcess for preparing aprotinin and aprotinin analogs in yeast cellsNOVO NORDISK AS·Filed 1993·Granted Jan 7, 1997·10 cites·13 claims
- 2654US2006199766A1Pharmaceutical composition comprising a factor VIIa and a factor XIIINOVO NORDISK HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 2754US2004143099A1Tissue factor antagonist and blood glucose regulator compositionsFiled 2003·Application pending·0 cites
- 2854US2004198660A1Tissue factor antagonist and protein C polypeptide compositionsFiled 2003·Application pending·0 cites
- 2952US5621074AAprotinin analogsNOVO NORDISK AS·Filed 1995·Granted Apr 15, 1997·12 cites·3 claims
- 3052US2007232542A1Methods for Modifying Cell Motility Using Factor VIIa AntagonistNOVO NORDISK AS·Filed 2007·Application pending·0 cites
- 3151US2004152633A1Kunitz-type sequences and polypeptidesFiled 2003·Application pending·0 cites
- 3250US2004072755A1TF antagonistFiled 2003·Application pending·0 cites
- 3348US2005239708A1Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxisNOVO NORDISK HEALTHCARE AG·Filed 2005·Application pending·0 cites
- 3448US2005245449A1Methods for modifying cell motility using factor VIIa antagonistNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 3547US6039944AModified Factor VIIZYMOGENETICS INC·Filed 1995·Granted Mar 21, 2000·10 cites·19 claims
- 3647US2012178908A1Targeting tissue factor to activated plateletsHILDEN IDA·Filed 2010·Application pending·0 cites
- 3746US5618915AAprotinin analogsNOVO NORDISK AS·Filed 1995·Granted Apr 8, 1997·4 cites·18 claims
- 3844US2003040481A1Methods for modifying cell motility using a factor VIIa antagonistFiled 2002·Application pending·0 cites
- 3944US2007213265A1Kunitz-type sequences and polypeptidesNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 4042US2002193302A1Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxisFiled 2002·Application pending·0 cites
- 4135US6168789B1Modified factor VIIZYMOGENETICS INC·Filed 1998·Granted Jan 2, 2001·1 cites·8 claims
- 4233US9260518B2Antibodies that are capable of specifically binding tissue factor pathway inhibitorHILDEN IDA·Filed 2011·Granted Feb 16, 2016·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Lars Christian Petersen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →